Theresa Lavallee News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Coherus BioSciences, Inc (NASDAQ:CHRS) Q1 2024 Earnings Call Transcript

Coherus BioSciences, Inc (NASDAQ:CHRS) Q1 2024 Earnings Call Transcript
insidermonkey.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from insidermonkey.com Daily Mail and Mail on Sunday newspapers.

United statesPuerto ricoTheresa lavalleeBrian mcmichaelPaul reiderPaul reederRaj diazJonathan nemanYigal nochomovitzNeulasta onproBryan mcmichaelChristopher hunterMichael nedelcovychCoherus biosciencesJamie taylorDennis lanfear

Coherus BioSciences, Inc (NASDAQ:CHRS) Q1 2024 Earnings Call Transcript

Coherus BioSciences, Inc (NASDAQ:CHRS) Q1 2024 Earnings Call Transcript
yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.

United statesChristopher hunterBryan mcmichaelNeulasta onproRosh diasYigal nochomovitzBrian mcmichaelTheresa lavalleeDenny lanfearCancer research instituteAmerican association of immunologists congressUniversity of pennsylvaniaChief medicalChief development officerAmerican associationImmunologists congress

Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting

– In preclinical studies, CHS-1000 shows a high affinity for human ILT4, reverses ILT4-mediated immunosuppressive functions, leading to activation of immune cells and increased cytokine secretion.

San diegoUnited statesJami taylorCoherus biosciencesJodi sieversNarendiran rajasekaranTheresa lavalleeExchange commission onExchange commissionCoherus biosciences incCorporate communicationsAmgen incAbbvie incChief development officerImmune checkpointsInhibitory molecules

Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR

–In preclinical studies, CHS-1000 shows a high affinity for human ILT4, reverses ILT4-mediated immunosuppressive functions, leading to activation of immune cells and increased cytokine secretion–

San diegoUnited statesCoherus biosciencesNarendiran rajasekaranTheresa lavalleeJodi sieversJami taylorAbbvie incExchange commission onExchange commissionCoherus biosciences incAmgen incCorporate communicationsChief development officerImmune checkpointsInhibitory molecules

Coherus BioSciences, Inc (NASDAQ:CHRS) Q3 2023 Earnings Call Transcript

Operator: Good day and thank you for standing by. Welcome to the Coherus Biosciences Third Quarter 2023 Conference Call. At this time all participants are in a listen-only mode.

Paul reiderDenny lanfearCoherus biosciencesRosh diasYigal nochomovitzMcdavid stilwellRobyn karnauskasDennis lanfearNeulasta onproTheresa lavalleeJamie taylorMark cuban cost plus drug companyCoherus biosciences incMost valuable financial companiesCharming shoppes incTeam cuban card